We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment with Sequential Intravenous or Oral Moxifloxacin Was Associated with Faster Clinical Improvement than Was Standard Therapy for Hospitalized Patients with Community-Acquired Pneumonia Who Received Initial Parenteral Therapy.
- Authors
Welte, Tobias; Petermann, Wolfgang; Schuermann, Dirk; Thomas Bauer, Torsten; Reimnitz, Peter
- Abstract
Background. Although third-generation cephalosporins, such as ceftriaxone (CTRX), and pneumococcal fluoroquinolones, such as moxifloxacin (MXF), are currently recommended first-line antibiotics for empirical treatment of inpatients with community-acquired pneumonia, CTRX and MXF have never undergone a head-to-head comparison. We therefore compared the efficacy, safety, and speed and quality of defervescence of sequential intravenous or oral MXF and high-dose CTRX with or without erythromycin (CTRX ± ERY) for patients with community-acquired pneumonia requiring parenteral therapy. Methods. In this prospective, multicenter, randomized, controlled, nonblinded study, 397 patients were randomly assigned to receive either MXF (400 mg once daily intravenously, possibly followed by oral tablets) or CTRX (2 g intravenously once daily) with or without ERY (1 g intravenously every 6-8 h) for 7-14 days. Results. Among 317 patients evaluable for efficacy and safety, 138 (85.7%) of 161 MXF-treated patients and 135 (86.5%) of 156 CTRX ± ERY-treated patients (59 [37.8%] of whom received CTRX and ERY) achieved continued clinical resolution. Defervescence and relief of symptoms, such as chest pain, occurred significantly earlier in the MXF-treated group than in the CTRX ± ERY-treated group. Both regimens were generally well tolerated. Conclusions. For adult patients hospitalized with community-acquired pneumonia, sequential MXF therapy was clinically equivalent to high-dose CTRX ± ERY therapy but led to a faster clinical improvement.
- Subjects
PNEUMONIA; PARENTERAL therapy; MOXIFLOXACIN; CHEST pain; CEPHALOSPORINS; BETA lactam antibiotics
- Publication
Clinical Infectious Diseases, 2005, Vol 41, Issue 12, p1697
- ISSN
1058-4838
- Publication type
Article